MA52424A - Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide - Google Patents
Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamideInfo
- Publication number
- MA52424A MA52424A MA052424A MA52424A MA52424A MA 52424 A MA52424 A MA 52424A MA 052424 A MA052424 A MA 052424A MA 52424 A MA52424 A MA 52424A MA 52424 A MA52424 A MA 52424A
- Authority
- MA
- Morocco
- Prior art keywords
- oxazepane
- benzoxazol
- carboxamide
- dihydro
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862636944P | 2018-03-01 | 2018-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52424A true MA52424A (fr) | 2021-01-06 |
Family
ID=66102025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052424A MA52424A (fr) | 2018-03-01 | 2019-03-01 | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210369732A1 (fr) |
EP (1) | EP3758708A1 (fr) |
JP (2) | JP7336450B2 (fr) |
KR (1) | KR20210014621A (fr) |
CN (1) | CN112055593B (fr) |
AU (1) | AU2019228717A1 (fr) |
CA (1) | CA3091707A1 (fr) |
MA (1) | MA52424A (fr) |
WO (1) | WO2019166626A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2699580T3 (fr) | 2014-01-24 | 2018-02-24 | ||
US20180028541A1 (en) * | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
AU2022218443A1 (en) * | 2021-02-05 | 2023-09-21 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
EP4329767A1 (fr) * | 2021-04-29 | 2024-03-06 | Insmed Incorporated | <smallcaps/>? ? ?n? ? ? ? ?certains-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement de la fibrose kystique |
WO2023134656A1 (fr) * | 2022-01-11 | 2023-07-20 | 上海壹典医药科技开发有限公司 | Composé de peptidyle nitrile et son utilisation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
EA200971133A1 (ru) * | 2004-06-29 | 2010-10-29 | Никомед Данмарк Апс | Производство фармацевтических композиций с быстрым высвобождением на основе водонерастворимых лекарственных средств и фармацевтические композиции, получаемые способом по изобретению |
UY31867A (es) * | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
BRPI1016132B8 (pt) * | 2009-04-01 | 2021-05-25 | Bial Portela & Ca Sa | composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável |
LT3150198T (lt) * | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
NO2699580T3 (fr) | 2014-01-24 | 2018-02-24 | ||
GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
EP4074312A1 (fr) * | 2014-04-10 | 2022-10-19 | Novartis AG | Régime posologique à libération immédiate de modulateurs s1p pour le traitement de maladies auto-immunes |
US20180028541A1 (en) * | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
-
2019
- 2019-03-01 EP EP19716296.9A patent/EP3758708A1/fr active Pending
- 2019-03-01 CA CA3091707A patent/CA3091707A1/fr active Pending
- 2019-03-01 JP JP2020545547A patent/JP7336450B2/ja active Active
- 2019-03-01 WO PCT/EP2019/055138 patent/WO2019166626A1/fr active Application Filing
- 2019-03-01 AU AU2019228717A patent/AU2019228717A1/en active Pending
- 2019-03-01 US US16/975,292 patent/US20210369732A1/en active Pending
- 2019-03-01 MA MA052424A patent/MA52424A/fr unknown
- 2019-03-01 KR KR1020207028037A patent/KR20210014621A/ko unknown
- 2019-03-01 CN CN201980028494.5A patent/CN112055593B/zh active Active
-
2023
- 2023-08-21 JP JP2023133951A patent/JP2023156480A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019228717A1 (en) | 2020-09-17 |
CN112055593B (zh) | 2024-04-09 |
JP7336450B2 (ja) | 2023-08-31 |
US20210369732A1 (en) | 2021-12-02 |
EP3758708A1 (fr) | 2021-01-06 |
JP2023156480A (ja) | 2023-10-24 |
JP2021515006A (ja) | 2021-06-17 |
CA3091707A1 (fr) | 2019-09-06 |
KR20210014621A (ko) | 2021-02-09 |
WO2019166626A1 (fr) | 2019-09-06 |
CN112055593A (zh) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52424A (fr) | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide | |
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
NO2022023I1 (no) | Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof | |
EA201290984A1 (ru) | Гелеобразные фармацевтические композиции, препятствующие злоупотреблению | |
DOP2010000326A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
DK3805233T3 (da) | (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling | |
EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
EA201300342A1 (ru) | Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов | |
NZ611868A (en) | Gastric and colonic formulations and methods for making and using them | |
CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
MX338413B (es) | Formulaciones de pelicula para los dientes. | |
BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
DK3661373T3 (da) | Farmaceutisk sammensætning mod anæmi | |
AR100453A1 (es) | Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física | |
CY1119695T1 (el) | Κρυσταλλικη μορφη της (s)-(2-(6-xλωpo-7- μεθυλ-1η-βενζο [d]ιμιδαζολ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ) φαινυλ) μεθανονης και η χρηση της ως ανταγωνιστης υποδοχεα ορεξινης | |
DK3866767T3 (da) | Farmaceutisk sammensætning til oral indgivelse omfattende aminopyrimidinderivat eller salt deraf | |
MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
EA201991287A1 (ru) | Твердые фармацевтические композиции на основе тикагрелора для перорального применения | |
EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения | |
BR112018004291A2 (pt) | composição farmacêutica incluindo dutasterida e formulação de cápsula compreendendo a mesma | |
BR112017000591A2 (pt) | antagonistas da neurocinina b na reprodução de peixes | |
MA54904A (fr) | Compositions pharmaceutiques comprenant du méloxicam | |
MA44859A (fr) | Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes | |
TN2018000175A1 (en) | Indane derivatives as mglur7 modulators |